Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): Normal versus heart failure

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 6, 2015, Pages 342-353

  Zhou, Peng ^a   Cheng, Che Ping ^a   Li, Tiankai ^a   Ferrario, Carlos M ^a   Cheng, Heng Jie ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

calcium; heart failure; ion currents; receptors; vasodilator agents

Indexed keywords

ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; BRADYKININ; CALCIUM CHANNEL L TYPE; G PROTEIN COUPLED RECEPTOR; ICATIBANT; ISOPRENALINE; MAS RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); CARDIOTONIC AGENT; NITRIC OXIDE; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CURRENT; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART FAILURE; HEART MUSCLE CELL; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; AGONISTS; ANIMAL; CALCIUM SIGNALING; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; MEMBRANE POTENTIAL; METABOLISM; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANGIOTENSIN I; ANIMALS; BRADYKININ; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HEART FAILURE; ISOPROTERENOL; MALE; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; NECROSIS; NITRIC OXIDE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84953243804     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944715587424     Document Type: Article

References (48)

1. Almeida A. Frabregas B. Madureira M. Santos R. Campagnole-Santos M. Santos R. (2000) Angiotensin-(1–7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res 33: 709–713.
2. Averill D. Ishiyama Y. Chappell M. Ferrario C. (2003) Cardiac angiotensin-(1–7) in ischemic cardiomyopathy. Circulation 108: 2141–2146.
3. Brosnihan K. Li P. Ferrario C. (1996) Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523–528.
4. Carey R. Siragy H. (2003) Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261–271.
5. Carvalho M. Duarte F. Faria-Silva R. Fauler B. da Mata Machado L. de Paula R. et al (2007) Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1–7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50: 762–767.
6. Cheng C. Suzuki M. Ohte N. Ohno M. Wang Z. Little W. (1996) Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78: 880–892.
7. Cheng C. Zhou P. Cheng H. Cross M. Little W. (2008) Direct cardiac effect and cellular mechanism of angiotensin-(1–7) in heart failure. Circulation 118(Suppl. 2): abstract S 513.
8. Crackower M. Sarao R. Oudit G. Yagil C. Kozieradzki I. Scanga S. et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822–828.
9. de Mello W. (2004) Angiotensin (1–7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 5: 203–208.
10. de Mello W. (2009) Renin angiotensin system as a regulator of cell volume. Implications to myocardial ischemia. Curr Cardiol Rev 5: 65–68.
11. de Mello W. Ferrario C. Jessup J. (2007) Beneficial versus harmful effects of angiotensin (1–7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 8: 74–80.
12. Donoghue M. Hsieh F. Baronas E. Godbout K. Gosselin M. Stagliano N. et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87: E1-E9.
13. Ferrario C. (2011) ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens 20: 1–6.
14. Ferrario C. Ahmad S. Joyner J. Varagic J. (2010) Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1–7). Adv Pharmacol 59: 197–233.
15. Ferrario C. Chappell M. Tallant E. Brosnihan K. Diz D. (1997) Counterregulatory actions of angiotensin-(1–7). Hypertension 30: 535–541.
16. Ferrario C. Jaiswal N. Yamamoto K. Diz D. Schiavone M. (1991) Hypertensive mechanisms and converting enzyme inhibitors. Clin Cardiol 14: IV56–IV62.
17. Ferrario C. Martell N. Yunis C. Flack J. Chappell M. Brosnihan K. et al (1998) Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 11: 137–146.
18. Ferrario C. Smith R. Brosnihan B. Chappell M. Campese V. Vesterqvist O. et al (2002) Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens 15: 557–564.
19. Ferrario C. Varagic J. (2010) The ANG-(1–7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 298: F1297–F1305.
20. Ferreira A. Santos R. Almeida A. (2001) Angiotensin-(1–7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38: 665–668.
21. Hamill O. Marty A. Neher E. Sakmann B. Sigworth F. (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85–100.
22. Hatem S. Sham J. Morad M. (1994) Enhanced Na(+)-Ca2+ exchange activity in cardiomyopathic Syrian hamster. Circ Res 74: 253–261.
23. Horn R. Marty A. (1988) Muscarinic activation of ionic currents measured by a new whole-cell recording method. J Gen Physiol 92: 145–159.
24. Iyer S. Ferrario C. Chappell M. (1998) Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356–361.
25. Liu E. Xu Z. Li J. Yang S. Yang W. Li G. (2011) Enalapril, irbesartan, and angiotensin-(1–7) prevent atrial tachycardia-induced ionic remodeling. Int J Cardiol 146: 364–370.
26. Loot A. Roks A. Henning R. Tio R. Suurmeijer A. Boomsma F. et al (2002) Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548–1550.
27. Luque M. Martin P. Martell N. Fernandez C. Brosnihan K. Ferrario C. (1996) Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 14: 799–805.
28. Maia L. Ramos M. Fernandes L. de Carvalho M. Campagnole-Santos M. Souza dos Santos R. (2004) Angiotensin-(1–7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 43: 685–691.
29. Marques F. Ferreira A. Sinisterra R. Jacoby B. Sousa F. Caliari M. et al (2011) An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 57: 477–483.
30. Ming Z. Nordin C. Siri F. Aronson R. (1994) Reduced calcium current density in single myocytes isolated from hypertrophied failing guinea pig hearts. J Mol Cell Cardiol 26: 1133–1143.
31. Ouadid H. Albat B. Nargeot J. (1995) Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 25: 282–291.
32. Pfeffer M. Pfeffer J. Fishbein M. Fletcher P. Spadaro J. Kloner R. et al (1979) Myocardial infarct size and ventricular function in rats. Circ Res 44: 503–512.
33. Pinheiro S. Simoes E. Silva A. Sampaio W. de Paula R. Mendes E. Bontempo E. et al (2004) Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490–496.
34. Rona G. (1985) Catecholamine cardiotoxicity. J Mol Cell Cardiol 17: 291–306.
35. Rossner K. (1991) Calcium current in congestive heart failure of hamster cardiomyopathy. Am J Physiol 260: H1179–H1186.
36. Santos P. Barcellos L. Mill J. Masuda M. (1995) Ventricular action potential and L-type calcium channel in infarct-induced hypertrophy in rats. J Cardiovasc Electrophysiol 6: 1004–1014.
37. Santos R. Castro C. Gava E. Pinheiro S. Almeida A. Paula R. et al (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor MAS knockout mice. Hypertension 47: 996–1002.
38. Santos R. Simoes e Silva A. Maric C. Silva D. Machado R. de Buhr I. et al (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
39. Schindler C. Bramlage P. Kirch W. Ferrario C. (2007) Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy. Vasc Health Risk Manag 3: 125–137.
40. Silva D. Vianna H. Cortes S. Campagnole-Santos M. Santos R. Lemos V. (2007) Evidence for a new angiotensin-(1–7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 28: 702–707.
41. Stewart J. Jr. Lazartigues E. Lucchesi P. (2008) The angiotensin converting enzyme 2/Ang-(1–7) axis in the heart: a role for MAS communication? Circ Res 103: 1197–1199.
42. Suzuki M. Ohte N. Wang Z. Williams D. Jr. Little W. Cheng C. (1998) Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Cardiovasc Res 39: 589–599.
43. Tallant E. Ferrario C. Gallagher P. (2005) Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566.
44. Teerlink J. Pfeffer J. Pfeffer M. (1994) Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 75: 105–113.
45. Wiemer G. Dobrucki L. Louka F. Malinski T. Heitsch H. (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium. Hypertension 40: 847–852.
46. Yuill K. McNeish A. Kansui Y. Garland C. Dora K. (2010) Nitric oxide suppresses cerebral vasomotion by sGC-independent effects on ryanodine receptors and voltage-gated calcium channels. J Vasc Res 47: 93–107.
47. Zhang Z. Cheng H. Onishi K. Ohte N. Wannenburg T. Cheng C. (2005) Enhanced inhibition of L-type Ca 2+ current by beta 3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther 315: 1203–1211.
48. Zisman L. Keller R. Weaver B. Lin Q. Speth R. Bristow M. et al (2003) Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE 2. Circulation 108: 1707–1712.